1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Anti-epileptic Drugs Market
2.2. Global Anti-epileptic Drugs Market, By Drug Class, 2023 (US$ Million)
2.3. Global Anti-epileptic Drugs Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Anti-epileptic Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Anti-epileptic Drugs Market Vendors
3.2. Strategies Adopted by Anti-epileptic Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Anti-epileptic Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Anti-epileptic Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Hydantoin derivatives
5.3.1.1. Phenytoin
5.3.1.2. Fosphenytoin
5.3.2. Iminostilbenes
5.3.2.1. Carbamazepine
5.3.2.2. Oxcarbazepine
5.3.3. Long acting barbiturates
5.3.3.1. Phenobarbitone
5.3.3.2. Methobarbitone
5.3.4. Succinimides
5.3.4.1. Ethosuximide
5.3.4.2. Methsuximide
5.3.4.3. Phensuximide
5.3.5. Benzodiazepines
5.3.5.1. Clonazepam
5.3.5.2. Nitrazepam
5.3.5.3. Diazepam
5.3.6. Carbonic anhydrase inhibitors (CAI)
5.3.6.1. Acetazolamide
5.3.6.2. Sulthiame
5.3.7. GAMA- vinyl – GABA
5.3.7.1. Vigabatrin
5.3.8. Amino acid derivatives
5.3.8.1. GABA pentin
5.3.9. Monosaccharide derivatives
5.3.9.1. Topiramate
5.3.10. Others


6. North America Anti-epileptic Drugs Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
6.3.Anti-epileptic Drugs Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)

7. UK and European Union Anti-epileptic Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.Anti-epileptic Drugs Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)

8. Asia Pacific Anti-epileptic Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.Anti-epileptic Drugs Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)

9. Latin America Anti-epileptic Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.3.Anti-epileptic Drugs Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)

10. Middle East and Africa Anti-epileptic Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.3.Anti-epileptic Drugs Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Anti-epileptic Drugs Market: By Drug Class, 2022-2032, USD (Million)

11. Company Profile
11.1. Abide Therapeutics
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Advicenne Pharma SA
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Alexza Pharmaceuticals
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Argentum Pharmaceuticals
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. GlaxoSmithKline (GSK) plc
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. GW Pharmaceuticals Plc
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Janssen Pharmaceuticals
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Marinus Pharmaceuticals
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Novartis Pharmaceuticals Corp
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Otsuka Pharmaceuticals
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Pfizer Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Takeda Pharmaceutical Company Ltd
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. UCB Pharma
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives